Table 2

Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010

Sarah E. Smith

, Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, and J. Peter Cegielski

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.E. Smith, J. Ershova, E. Kurbatova, J.P. Cegielski); Arkhangelsk Regional Tuberculosis Dispensary, Arkhangelsk, Russia (N. Vlasova, E. Nikishova, I. Tarasova, P. Eliseev, A.O. Maryandyshev); Northern State Medical University, Arkhangelsk (A.O. Maryandyshev); State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia (I.G. Shemyakin)

Main Article

Risk factors for acquired resistance to CAP while receiving treatment for MDR TB, 158 patients, Arkhangelsk Oblast, Russia, 2005–2010*

Variable†	Total	Acquired capreomycin resistance, no. (%)		p value‡
Variable†	Total	Yes	No	p value‡
Received ≥3 effective drugs
Yes	126	0	126 (100)	0.008
No	32	3 (9.4)	29 (90.6)
Ever received effective FQ treatment§
Yes	148	1 (0.7)	147 (99.3)	0.009
No	9	2 (22.2)	7 (77.8)
Ever received effective PAS treatment§
Yes	110	0 (0)	110 (100)	0.02
No	46	3 (6.5)	43 (93.5)
Previous treatment with FQ
Yes	28	2 (7.1)	26 (92.9)	0.08
No	130	1 (0.8)	129 (99.2)
Previous PAS treatment¶
Yes	23	2 (8.7)	21 (91.3)	0.08
No	112	1 (0.9)	111 (99.1)
First time patient treated for MDR TB
Yes	134	1 (0.7)	133 (99.3)	0.06
No	24	2 (8.3)	22 (91.7)
Baseline ofloxacin DST result
Resistant	9	2 (22.2)	7 (77.8)	0.008
Susceptible	149	1 (0.7)	148 (99.3)
Baseline PAS DST result
Resistant	47	3 (6.4)	44 (93.6)	0.03
Susceptible	111	0 (0)	111 (100)
Received OFX during episode
Yes	135	0 (0)	135 (100)	0.003
No	23	3 (13)	20 (87)
Received MOX during episode
Yes	31	3 (9.7)	28 (90.3)	0.007
No	127	0 (0)	127 (100)

*CAP, capreomycin; DST, drug-susceptibility test; FQ, fluoroquinolone; MDR TB, multidrug-resistant tuberculosis; MOX, moxifloxacin; OFX, ofloxacin; PAS, para-aminosalicylic acid.
†Certain variables were tested for association but omitted from table because results were not statistically significant at α = 0.1.
‡Fisher exact test.
§Patient(s) who did not receive treatment with the respective drug during the current episode of MDR TB were not included in the analysis.
¶For 23 patients, history of treatment with PAS was unknown.

Main Article

Page created: May 15, 2015

Page updated: May 15, 2015

Page reviewed: May 15, 2015

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.